UK markets closed
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • FTSE 250

    20,593.46
    -21.23 (-0.10%)
     
  • AIM

    889.79
    +1.03 (+0.12%)
     
  • GBP/EUR

    1.1163
    -0.0042 (-0.37%)
     
  • GBP/USD

    1.2056
    -0.0173 (-1.41%)
     
  • BTC-GBP

    19,367.92
    -158.22 (-0.81%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • DOW

    33,926.01
    -127.93 (-0.38%)
     
  • CRUDE OIL

    73.23
    -2.65 (-3.49%)
     
  • GOLD FUTURES

    1,865.90
    -50.40 (-2.63%)
     
  • NIKKEI 225

    27,509.46
    +107.41 (+0.39%)
     
  • HANG SENG

    21,660.47
    -297.89 (-1.36%)
     
  • DAX

    15,476.43
    -32.76 (-0.21%)
     
  • CAC 40

    7,233.94
    +67.67 (+0.94%)
     

Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed

Johnson & Johnson Could Level Up With Its $16.8 Billion Purchase of Abiomed

Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) recently made headlines by announcing it will acquire medical device company Abiomed for $16.6 billion in an all-cash transaction. The buyout offer was roughly a 50% premium to where shares of Abiomed traded at the time of the announcement, signaling Johnson & Johnson's desire to make the deal happen. Few companies have the financial firepower Johnson & Johnson has, so I'll break down the acquisition's financial impact and whether Abiomed will make its new parent company a better investment for long-term investors.